First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Johnson & Johnson (JNJ): the developments shaping its investment case

    Follow the evidence affecting Johnson & Johnson's valuation assumptions, demand outlook, margins. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Johnson & Johnson · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-09-18
    10-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiums
    Channel: Increased competition for passive income from risk-free assets; higher discount rates reduce present value of future dividends.
    Bearish· 1-3m
    2026-09-15 · 7 reports
    Citadel increases AbbVie stake over 500% amid institutional yield rotation
    Channel: Second-order effect: Similar characteristics (large-cap, healthcare, dividend payer) make it a likely beneficiary of the same institutional yield rotation.
    Bullish· 1-3m
    2026-09-15 · 2 reports
    Citadel Expands AbbVie Stake by Over 500% in Q2 2026
    Channel: Sector-wide positive sentiment for defensive healthcare stocks; potential for capital rotation into stable pharma.
    Bullish· 1-3m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-09-12multipleBullishTarget re-rates to bid premium until close.
    2026-07-15revenueBullishCompany raised 2026 guidance to $101.1 Billion midpoint based on strong operational performance.
    2026-07-15revenueBullishCompany raised 2026 sales guidance to $101.1 Billion at the midpoint.
    2026-07-15revenueBullishCompany raised 2026 guidance with estimated reported sales of $101.1 Billion.
    2026-07-15share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-07-15net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-07-15revenueBullishAcquisition adds target revenue to acquirer P&L on close.
    2026-07-15marginBullishCompany increased adjusted EPS guidance by $0.13 to $11.68.
    2026-07-15revenueBullishCompany raised 2026 guidance to estimated reported sales of $101.1 Billion.

    Event impact log

    71 events mapped to JNJ since 2026-08-11. Evidence through 2026-09-26.

    DateEventChannelDirectionHorizonImpact
    2026-09-26C4 Therapeutics Presents Cemsidomide Multiple Myeloma Phase 1 Biomarker DataPotential future competition in the multiple myeloma market, specifically for elranatamab, if cemsidomide progresses.watch3-12m0.20
    2026-09-26C4 Therapeutics presents cemsidomide Phase 1 biomarker data at IMSIndirect competitive landscape implications in multiple myeloma.watch3-12m0.20
    2026-09-24Vistagen Reports Positive Findings Supporting Fasedienol’s Potential in Very Severe Social Anxiety DisorderPotential competitive landscape shift in mental health therapeutics. J&J has a broad pharmaceutical portfolio and may be interested in or impacted by new treatments for anxiety disorders.watch3-12m0.10
    2026-09-24Kyverna Therapeutics Reports Positive One-Year Data for Miv-cel; Rolling BLA Submission on Track for Q4 2026Potential competitive pressure or validation of the CAR T cell therapy approach in autoimmune diseases. J&J has an interest in cell therapies.watch3-12m0.20
    2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMOIncreased competitive pressure in the EGFR-mutated NSCLC market, particularly for patients developing MET-driven resistance, potentially impacting future market share for competing therapies.Bearish3-12m0.30
    2026-09-21Alkermes Announces Positive Phase 1b Results for ALKS 7290 in Adults With ADHDPotential future competition in the ADHD market, particularly for novel mechanisms of action.watch1-5y0.20
    2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as New Therapies Reach 60% of MixIndirect competitive and investor sentiment. As a diversified healthcare giant, JNJ's pharmaceutical segment competes with BMY. BMY's strong performance in new drug adoption could subtly influence investor expectations for innovation across the industry.mixed3-12m0.10
    2026-09-21Bristol Myers Squibb growth portfolio reaches 60% of revenue with 153% Q2 EPS growthSimilar to PFE, BMY's successful product transition offers a benchmark for other diversified healthcare giants managing their own drug pipelines and patent expirations. It could also intensify competition.mixed1-3m0.30
    2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%Indirect sector sentiment and comparative strategic execution.watch3-12m0.20
    2026-09-21Bristol Myers Squibb Growth Portfolio Reaches 60% of Revenue in Q2Diversified healthcare conglomerate with a significant pharmaceutical segment. BMY's performance offers insights into the competitive landscape and investor appetite for pharmaceutical innovation.mixed3-12m0.40
    2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment ContinuityPotential competitive pressure on J&J's long-acting injectable antipsychotics (e.g., Invega Sustenna/Trinza) due to UZEDY's demonstrated superiority in real-world adherence and cost-effectiveness.Bearish1-3m0.40
    2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantageUZEDY competes in the schizophrenia treatment market. Improved data for Teva's UZEDY could potentially increase competitive pressure on J&J's long-acting injectable antipsychotics (e.g., Invega Sustenna/Trinza), potentially affecting their market share or pricing power over time.watch3-12m0.20
    2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsIncreased competitive pressure on J&J's long-acting injectable schizophrenia treatments (e.g., Invega Sustenna/Trinza) due to Teva's UZEDY demonstrating superior real-world outcomes and cost-effectiveness, potentially leading to slower growth or market share erosion.Bearish3-12m0.40
    2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia ContinuityIncreased competitive pressure on long-acting injectable antipsychotics, potentially impacting market share and pricing.Bearish3-12m0.40
    2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost ReductionsIncreased competitive pressure and potential market share erosion for their long-acting injectable antipsychotics (e.g., Invega Sustenna/Trinza) due to UZEDY's demonstrated superior outcomes and cost profile.Bearish3-12m0.50
    2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare UtilizationIncreased competitive pressure in the schizophrenia treatment market from UZEDY's improved clinical profile and potential for enhanced formulary access, potentially impacting market share for competing products.Bearish3-12m0.30
    2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting InjectablesIncreased competitive pressure on long-acting injectable antipsychotics, potentially leading to market share erosion or pricing pressure for their similar products.Bearish1-3m0.40
    2026-09-1810-Year Treasury yield approaches 5.0%, compressing defensive dividend risk premiumsIncreased competition for passive income from risk-free assets; higher discount rates reduce present value of future dividends.Bearish1-3m0.60
    2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel PathwaysSimilar to Pfizer, J&J has a broad pharmaceutical presence and could benefit from new opportunities but also face increased competition.mixed3-12m0.45
    2026-09-15Citadel increases AbbVie stake over 500% amid institutional yield rotationSecond-order effect: Similar characteristics (large-cap, healthcare, dividend payer) make it a likely beneficiary of the same institutional yield rotation.Bullish1-3m0.60
    2026-09-15Citadel Expands AbbVie Position Over 500% Amid Defensive Rotation and Dividend DemandBroader sector rotation into defensive healthcare, dividend-paying stocks, flight to quality.Bullish1-3m0.50
    2026-09-15Citadel Expands AbbVie Stake by Over 500% in Defensive RotationSecond-order effect: Potential for broader defensive sector rotation. If Citadel is increasing exposure to ABBV, other large-cap pharmaceutical/healthcare companies might also see increased interest.watch1-3m0.30
    2026-09-15Citadel Expands AbbVie Position Over 500% as Defensive Dividend Demand RisesIncreased investor demand for defensive, dividend-paying stocks, particularly in the healthcare sector. JNJ is a well-known dividend aristocrat.Bullish1-3m0.50
    2026-09-15Citadel Expands AbbVie Position Over 500% in Q2 Amid Defensive RotationSecond-order effect: As a large-cap pharmaceutical company with a strong dividend and defensive characteristics, JNJ is likely to benefit from the same thematic rotation of institutional capital seeking safety and yield.Bullish1-3m0.60
    2026-09-15Citadel increases AbbVie position by over 500% amid defensive yield rotationPeer in defensive healthcare/biopharma sector, likely to benefit from similar defensive yield rotation.Bullish1-3m0.50
    2026-09-15Citadel Expands AbbVie Stake by Over 500% in Q2 2026Sector-wide positive sentiment for defensive healthcare stocks; potential for capital rotation into stable pharma.Bullish1-3m0.50
    2026-09-15Citadel expands AbbVie stake over 500% in Q2 defensive positioning moveSector-wide positive sentiment spillover for large-cap, defensive pharmaceutical companies with strong dividends, as institutional investors seek similar characteristics.Bullish1-3m0.50
    2026-09-15Citadel Expands AbbVie Holding by Over 500% as Defensive Dividend Yield Draws CapitalSimilar to ABT, JNJ is a large-cap, diversified healthcare company with a strong dividend history, often considered a defensive play. The capital flow into ABBV could indicate a broader institutional preference for such assets, potentially benefiting JNJ as well.watch1-3m0.30
    2026-09-15Citadel Expands AbbVie Stake Over 500% as High Yields Drive Defensive RotationSecond-order effect: Sector rotation into defensive healthcare, high-quality cash flow, and dividend-paying stocks. JNJ shares similar characteristics to ABBV.Bullish1-3m0.60
    2026-09-14The Cooper Companies Lowers Full-Year Organic Guidance on Channel DestockingSecond-order effect: J&J's Vision Care segment (Acuvue contact lenses) operates in the same market as CooperVision. Destocking at distributors could indicate broader market trends or competitive pressures.watch1-3m0.30
    2026-09-14Cooper Companies Drops 14.6% as Channel Destocking Cuts Full-Year GuidanceSecond-order effect: J&J's Vision Care segment (Acuvue contact lenses) operates in the same market and utilizes similar distribution channels. Destocking at distributors for one major player could indicate a broader trend affecting others.watch1-3m0.40
    2026-09-13Cooper Companies Cuts Organic FY Guidance on U.S. Channel DestockingSecond-order effect: Potential for similar channel destocking in other medical device or consumer health segments, particularly those with significant U.S. distributor networks. J&J has a large Vision Care segment (Acuvue).watch1-3m0.30
    2026-09-13Eli Lilly Immunology Revenue Hits $2.6B in H1 2026, Growing 9% YoYIncreased competition in the immunology market from Eli Lilly's growing portfolio, potentially impacting J&J's immunology product sales.Bearish3-12m0.40
    2026-09-13Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New LaunchesCompetitive dynamics within the broader immunology market. J&J has a significant immunology franchise (e.g., Stelara, Tremfya, Darzalex), and LLY's strong performance signals an increasingly competitive environment for market share and new patient starts.mixed3-12m0.40
    2026-09-13The Cooper Companies Cuts Organic Guidance to Flat-to-Down 2% on Channel DestockingSecond-order effect: As a major player in the vision care market (Acuvue contact lenses), J&J could potentially face similar, albeit less severe, channel destocking pressures in the U.S. if the issue is industry-wide rather than company-specific.watch1-3m0.30
    2026-09-13Cooper Companies Cuts FY Guidance on U.S. Channel DestockingSecond-order effect: J&J's MedTech segment, including vision care (Acuvue), could face similar inventory adjustments from distributors if the trend observed by Cooper Companies is systemic rather than company-specific.watch1-3m0.30
    2026-09-13Cooper Companies Drops 14.6% on US Channel Destocking and Guidance CutIndirect read-across for its vision care segment (Acuvue contact lenses) and broader medical device portfolio, though JNJ's diversified nature mitigates impact.watch1-3m0.20
    2026-09-13Eli Lilly Immunology Division Reaches $2.6 Billion Revenue in H1 2026Increased competitive pressure in the immunology market from a strong player like Eli Lilly could impact market share or pricing power for J&J's immunology portfolio.mixed3-12m0.40
    2026-09-12Eli Lilly Immunology Division Reaches $2.6B in H1 2026 on Taltz and New LabelsIncreased competitive pressure in the immunology market, particularly for drugs like Stelara and Tremfya.mixed3-12m0.30
    2026-09-12Eli Lilly immunology revenue rises 9% in H1 2026 to $2.6B on DICE and Morphic M&AIntensified competition in the immunology therapeutic area, where J&J has significant market presence (e.g., Stelara, Tremfya), potentially affecting future growth rates or market share.mixed3-12m0.30

    Continue this research

    Build your Johnson & Johnson investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the JNJ entity page →

    Research Johnson & Johnson · $399/mo